Amneal receives EU approval for omalizumab biosimilar
At a glance
- $AMRX today−0.52%last $21.12
- Vs industry peers+0.33 pts6-peer median −0.85% · in step
- Since it broke0.00%from the first trade after the story
- 52-week range4.3% below high$11.39 – $22.07
- Last reported loss$21.7Mquarter to Sep 30, 2026 · 10-Q
- Coverage1 this week1 in 30 days · too few stories to call a pace
Nothing reported about amneal across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Approvals and strong trial data can reprice a drugmaker quickly — especially when one product is most of the company.
- How the stock is trading: $AMRX -0.52% in the latest session.
- Timing: It came out after the closing bell. The session change shown was settled before the story existed, and the next session is the first that could react.
Where the stock stands
Amneal Pharmaceuticals ($AMRX) edged down 0.52% to $21.12 in the latest session. Over the past month it is up 9.1%. It now sits 4.3% under the 52-week high of $22.07 and 85% above the year's low of $11.39, close to the top of its range. The high sits 94% above the low, a wide range for one year.
What the filings say
In its latest report (10-Q, filed Nov 9, 2026), $AMRX lost $21.7M over the quarter to Sep 30, 2026 on revenue of $862.7M (+8.4% QoQ). Operations brought in $50.3M of cash over the nine months to Sep 30, 2026; after capital spending, free cash flow was negative at $20.3M. It carried $2.94B of debt against $157.4M of cash on Sep 30, 2026 — net debt of $2.78B. Its most recent filings before this story: 10-Q on Nov 9, 2026, 8-K on Nov 3, 2026, 8-K on Aug 10, 2026. Figures are as filed with the SEC; the $AMRX page has the full statements.
How much coverage it is getting
Wook has no other story on Amneal Pharmaceuticals from the last 30 days, so there is no recent run to compare this one with.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
For the company's side of it, read its latest SEC filings on the $AMRX page. A US company has to report material news on an 8-K, usually within four business days; foreign issuers use a 6-K. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. To run the numbers yourself, ask Wook AI above about $AMRX: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 17, 2026. $AMRX has moved +0.00% ($21.12 to $21.12). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
